Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ATM I2629fs ATM neg||endometrial clear cell adenocarcinoma||predicted - sensitive||BAY1895344||Case Reports/Case Series||Actionable||In a Phase I trial, BAY1895344 treatment resulted in a partial response with a 53% decrease in tumor size in a patient with clear cell endometrial cancer harboring ATM I2629fs with ATM protein loss, treatment was ongoing at 433 days (PMID: 32988960; NCT03188965).||32988960|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|